David Ricks, Eli Lilly CEO (Evan Vucci/AP Images)
August 17, 2021 07:38 AM EDT
Pharma

Eli Lil­ly un­veils a com­plete makeover, erect­ing a neu­ro­science unit cen­tered on Alzheimer's as it uni­fies on­col­o­gy biz

Kyle Blankenship

The FDA ap­proval of Bio­gen’s Aduhelm for Alzheimer’s has breathed new life in­to neu­rol­o­gy units across bio­phar­ma, none more so than near­est ri­val Eli Lil­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Lil­ly inks obe­si­ty deal with seed-stage RNA start­up as its ge­net­ic med­i­cines ef­fort en­ters the spot­light

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times